Prostate cancer

Relevant risk variants from the literature

---

Population: Males of European ancestry

Locus	Chromo- some	Variant / SNP	My Codes	Relative Risk	Genotype frequency	Num. Cases / Num. Controls
11p15	11	rs7127900	AG	1.12	32.0%	16229 / 14821
Eeles RA, et al. Nat Genet. 2009 Sep 20.
11q13	11	rs10896449	AA	0.81	23.0%	5000 / 5000
Thomas, G et al. Nat Genet. 2008 Mar;40(3):310-5. Epub 2008 Feb 10.
17q24	17	rs1859962	GG	1.21	21.2%	3500 / 14000
Gudmundsson, J et al. Nat Genet. 2007 Aug;39(8):977-83. Epub 2007 Jul 1.
19q13.2	19	rs8102476	CT	0.99	49.7%	13173 / 47198
Gudmundsson J, et al. Nat Genet. 2009 Sep 20.
22q13	22	rs5759167	GG	1.14	28.1%	16229 / 14821
Eeles RA, et al. Nat Genet. 2009 Sep 20.
2q31	2	rs10207654	AA	1.03	88.4%	16229 / 14821
Eeles RA, et al. Nat Genet. 2009 Sep 20.
3p12	3	rs2660753	CT	1.06	19.6%	7370 / 5742
Kote-Jarai, Z et al. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2052-61.
3q21.3	3	rs10934853	AA	1.17	8.1%	13774 / 47614
Gudmundsson J, et al. Nat Genet. 2009 Sep 20.
4q24	4	rs7679673	AC	0.99	49.5%	16229 / 14821
Eeles RA, et al. Nat Genet. 2009 Sep 20.
8p21	8	rs1512268	GG	0.86	30.2%	16229 / 14821
Eeles RA, et al. Nat Genet. 2009 Sep 20.
8q24.21	8	rs16902104	CC	0.94	72.2%	12102 / 16913
Gudmundsson J, et al. Nat Genet. 2009 Sep 20.
8q24.21	8	rs620861	CC	1.09	40.8%	8234 / 43651
Gudmundsson J, et al. Nat Genet. 2009 Sep 20.
8q24	8	rs10505483	GG	0.96	93.9%	2600 / 5500
Gudmundsson J, et al. Nat Genet. 2007 May;39(5):631-7. Epub 2007 Apr 1.
8q24	8	rs1447295	CC	0.91	82.4%	2000 / 5000
Gudmundsson J, et al. Nat Genet. 2007 May;39(5):631-7. Epub 2007 Apr 1.
8q24	8	rs10086908	TT	1.09	49.0%	5504 / 5834
Al Olama AA, et al. Nat Genet. 2009 Sep 20.
EHBP1	2	rs2710646	AC	1.09	30.8%	10000 / 29000
Gudmundsson, J et al. Nat Genet. 2008 Mar;40(3):281-3. Epub 2008 Feb 10.
JAZF1	7	rs10486567	GG	1.04	57.8%	5200 / 5133
Thomas, G et al. Nat Genet. 2008 Mar;40(3):310-5. Epub 2008 Feb 10.
KLK2/KLK3	19	rs2735839	AG	0.92	25.5%	7370 / 5742
Kote-Jarai, Z et al. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2052-61.
LMTK2	7	rs6465657	TT	0.90	28.1%	7370 / 5742
Kote-Jarai, Z et al. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2052-61.
MSMB	10	rs10993994	CT	1.03	48.0%	5000 / 5000
Thomas, G et al. Nat Genet. 2008 Mar;40(3):310-5. Epub 2008 Feb 10.
NUDT11	X	rs5945572	G	0.93	65.0%	10000 / 29000
Gudmundsson, J et al. Nat Genet. 2008 Mar;40(3):281-3. Epub 2008 Feb 10.
POU5F1P1	8	rs6983267	GT	0.99	50.0%	4300 / 4300
Yeager, M et al. Nat Genet. 2007 May;39(5):645-9. Epub 2007 Apr 1.
SLC22A3	6	rs9364554	CT	1.06	40.3%	7370 / 5742
Kote-Jarai, Z et al. Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2052-61.
TCF2	17	rs4430796	GG	0.82	26.2%	3500 / 14000
Gudmundsson, J et al. Nat Genet. 2007 Aug;39(8):977-83. Epub 2007 Jul 1.
TERT	5	rs401681	CC	1.06	30.2%	9473 / 37901
Rafnar, T et al. Nat Genet. 2009 Feb;41(2):221-7. Epub 2009 Jan 18.

Chromosome location of relevant variants

---

The figure below shows the genomic location of the relevant variants, represented as stripes across the chromosome. Their color indicates your relative risk (red: high risk, yellow: medium risk, green: low risk). Hover over the variants with the mouse cursor to obtain more detailed information.

Keep in mind

---

These are the results of calculations comparing your genetic sequence to sequence of participants in studies published in the world literature on genetic risk for this disease. Read more about how deCODEme calculates risks.

This test was developed and its performance characteristics determined by the deCODE genetics Diagnostic Laboratory. It has not been cleared or approved by the U. S. Food and Drug Administration (FDA).

Change history

---